Brand-name drugs have been having a rough patch in terms ofpublic relations.

Hospitals have restricted interaction between doctorsand pharmaceutical sales reps, pharma moguls are being hauledbefore congressional committees to be chastised for price-gouging,and at least one major medical association has advised its members to prescribegeneric drugs whenever possible because patients are more likely toactually buy them and take them as ordered.

A new study shows just how much more brand-name drugs arecosting consumers as well as the federal government. The study,published in Health Affairs, examined the price differences betweengenerics and brand names for those getting drugs through Medicare Part D.

Continue Reading for Free

Register and gain access to:

  • Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.